Published by Josh White on 17th December 2025
(Sharecast News) - Hutchmed said on Wednesday that it has initiated a global phase one clinical development programme for HMPL-A251, marking the first clinical-stage candidate from its next-generation Antibody-Targeted Therapy Conjugate platform.
URL: http://www.digitallook.com/dl/news/story/35570305/...